INTRODUCTION

38
Plasmodium vivax is responsible for more than 50% of malaria cases worldwide and is 39 prevalent in Southeast Asia, the Western Pacific, Central and South America. P. vivax malaria 40 is known for causing relapses (1) and in recent years complicated clinical conditions have 41 been reported for this type of malaria that are similar to those found for P. falciparum. Indeed, [Escriba texto] concentrations evaluated. The IC 50s were estimated using a dose-response regression model 117 from the drug-free controls by the GraphPad Prism version 5.0 program. The IC 50s that were 118 within the concentration range evaluated for each antimalarial, and that had an r 2 > 9.0, were 119 classified as valid. The IC 50 of each antimalarial was correlated with the antimalarial group to 120 which it belonged (aminoquinolines and artemisinins) in order to find overlapping 121 susceptibility.
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Statistical analysis: The statistical analysis was carried out using the GraphPad Prism 
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In vitro susceptibility of P. vivax to antimalarials
145
The number of valid tests and the IC 50 found for each antimalarial can be seen in Table 2 .
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Due to the fact that only 30 isolates matured successfully, the IC 50 medians were analysed 147 based on the predominance of the initial parasitic stages, as shown in (Table 5 ) (9, 19, 21, 22, 36, 38) . In this study, when the isolates were classified (Table 5) . (19, 22, 39 
